What does a low anti‑Müllerian hormone (AMH) level (~0.16 ng/mL) indicate in a 37‑year‑old woman with endometriosis, and how should it be managed?

Low AMH in Endometriosis: Interpretation and Management

What This AMH Level Indicates

An AMH of 0.16 ng/mL in a 37-year-old woman with endometriosis indicates severely diminished ovarian reserve (DOR), reflecting both age-related decline and the additional impact of endometriosis on ovarian function. 1, 2

Understanding the Context

• Women with endometriosis have significantly lower AMH levels (approximately 30% reduction) compared to those without the disease, with the effect being most pronounced in severe endometriosis (rAFS III-IV stages) 1, 3

• By age 36, median AMH values drop below 1.2 ng/mL in the general population, and the prevalence of DOR increases dramatically—from 15.9% at age 18 to 96% at age 45 2

• Women with endometriosis from specialized endometriosis units have median AMH levels of 1.6 ng/mL, significantly lower than the general population (2.03 ng/mL) 2

• At 0.16 ng/mL, this patient's AMH is well below even the endometriosis-affected population median, indicating severe compromise of ovarian reserve 2

Critical Distinction: AMH Does Not Equal Fertility Potential

Low AMH from endometriosis reflects reduced oocyte quantity but does NOT necessarily indicate poor oocyte quality or reduced pregnancy potential—this is a crucial counseling point. 4

• In women under 37 with severe endometriosis and AMH ≤1.1 ng/mL, oocyte yield is reduced but embryo quality, implantation rates (31% vs 33%), and pregnancy rates (50% vs 49%) remain comparable to controls with normal AMH 4

• Low AMH should not be used as a criterion to discourage IVF/ICSI treatment in younger women with endometriosis 4

• Postoperative AMH decline does not necessarily correlate with reduced fertility—women who achieved pregnancy showed no significant difference in post-surgical AMH levels compared to those who did not conceive 5

Management Algorithm

Immediate Fertility Assessment

• If pregnancy is desired now or in the near future, proceed urgently to reproductive endocrinology consultation—the combination of age 37 and AMH 0.16 ng/mL indicates a narrow window for intervention 6, 2

• Preoperative AMH >2 ng/mL is associated with significantly higher spontaneous pregnancy rates after endometriosis surgery; at 0.16 ng/mL, assisted reproductive technology (ART) is likely necessary 6

• Complete baseline infertility workup including partner evaluation, tubal patency assessment, and comprehensive pelvic imaging to identify deep infiltrating disease that may require surgical intervention before conception 7, 8

Imaging to Guide Treatment Planning

• Obtain transvaginal ultrasound (TVUS) as initial imaging, or proceed directly to MRI pelvis without IV contrast if deep infiltrating endometriosis is suspected based on symptoms (dysmenorrhea, deep dyspareunia, dyschezia, dysuria) 7

• If ovarian endometriomas are present, MRI with IV contrast is highly recommended to differentiate from ovarian malignancy, given the risk of endometriosis-associated malignancies 7

• Identify deep infiltrating disease involving bowel or urologic structures, as this may require surgical management prior to conception attempts 7, 8

Surgical Considerations

• If endometriomas are present and surgery is being considered, counsel extensively about further AMH decline—laparoscopic cystectomy causes additional AMH reduction, though levels may partially recover postoperatively 9, 5

• Risk factors for greater postoperative AMH decline include bilateral cysts, advanced surgical staging (rAFS III-IV), and completely enclosed pouch of Douglas 5

• Consider non-excisional surgery (drainage/ablation) for endometriomas to spare ovarian parenchyma, though temporary AMH decline still occurs 9

• If surgery is performed, use non-thermal hemostasis methods (suturing rather than electrocautery) to minimize ovarian damage 9

Fertility Treatment Strategy

• Given AMH 0.16 ng/mL at age 37, proceed directly to IVF/ICSI rather than attempting prolonged expectant management or ovulation induction—time is critical 6, 4, 2

• Anticipate lower oocyte yield during controlled ovarian hyperstimulation and adjust gonadotropin dosing accordingly 3

• Consider pre-conception hormonal suppression if adenomyosis coexists (often present with endometriosis), as this is associated with recurrent pregnancy loss 8

Common Pitfalls to Avoid

• Do not delay fertility treatment based solely on low AMH—in younger women with endometriosis, low AMH reflects quantity not quality 4

• Do not assume negative imaging excludes endometriosis—superficial peritoneal disease is poorly detected by all imaging modalities, and clinical diagnosis based on symptom patterns is sufficient to initiate empiric treatment 7

• Do not perform surgery solely for diagnostic purposes—laparoscopy with histologic confirmation is no longer required before initiating treatment, and surgery should be reserved for definitive management of deep infiltrating disease or endometriomas affecting fertility 7

• Be aware that 25-44% of patients experience symptom recurrence within 12 months even after appropriate treatment, requiring ongoing monitoring 8

Long-Term Considerations

• Women with endometriosis have increased cardiovascular risk, including 34% higher stroke risk (HR 1.34,95% CI 1.10-1.62)—address modifiable risk factors including hypercholesterolemia and hypertension 8

• Lower AMH levels in women with endometriosis may be one mechanism linking endometriosis to younger age at menopause and cardiovascular disease 1